Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
John Kavanagh
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Procedures
Chemicals & Drugs
Physiology
Concepts & Ideas
Sign-in to see full Profile
Network (preview)
74
Kudelka, Andrzej
59
Edwards, Creighton
53
Verschraegen, Claire
43
Freedman, Ralph
32
Gershenson, David
25
Hu, Wei
19
Wharton, Taylor
12
Levenback, Charles
12
Tresukosol, Damras
11
Termrungruanglert, Wichai
10
Stringer, Allen
10
Morris, Mitchell
10
Fu, Siqing
10
Copeland, Larry
10
Burke, Thomas
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of John Kavanagh (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Zheng Hong; Hu Wei; Deavers Michael T; Shen De-Yu; Fu Siqing; Li Yan-Fang; Kavanagh John J
Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer.
American journal of obstetrics and gynecology 2009;201(4):367.e1-6.
-
2009: Gershenson David M; Sun Charlotte C; Bodurka Diane; Coleman Robert L; Lu Karen H; Sood Anil K; Deavers Michael; Malpica Anais L; Kavanagh John J
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gynecologic oncology 2009;114(1):48-52.
-
2009: Jaishuen Atthapon; Jimenez Camilo; Sirisabya Nakarin; Li Yanfang; Zheng Hong; Hu Wei; Urbauer Diana L; Kavanagh John J
Poor survival outcome with moderate and severe hypercalcemia in gynecologic malignancy patients.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19(2):178-85.
-
2009: Li Yanfang; Hu Wei; Shen De-Yu; Kavanagh John J; Fu Siqing
Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis.
American journal of obstetrics and gynecology 2009;200(2):177.e1-9.
-
2008: Tao Xia; Chon Hye S; Fu Siqing; Kavanagh John J; Hu Wei
Update on aurora kinase inhibitors in gynecologic malignancies.
Recent patents on anti-cancer drug discovery 2008;3(3):162-77.
-
2008: Zheng Hong; Hu Wei; Yu Dongfang; Shen De-Yu; Fu Siqing; Kavanagh John J; Wei I-Chien; Yang David J
Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest.
Pharmaceutical research 2008;25(10):2272-82.
-
2008: Tao Xia; Hu Wei; Ramirez Pedro T; Kavanagh John J
Chemotherapy for recurrent and metastatic cervical cancer.
Gynecologic oncology 2008;110(3 Suppl 2):S67-71.
-
2008: Ramirez Pedro T; Schmeler Kathleen M; Milam Michael R; Slomovitz Brian M; Smith Judith A; Kavanagh John J; Deavers Michael; Levenback Charles; Coleman Robert L; Gershenson David M
Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum.
Gynecologic oncology 2008;110(1):56-9.
-
2008: Li Y F; Hu W; Fu S Q; Li J D; Liu J H; Kavanagh J J
Aromatase inhibitors in ovarian cancer: is there a role?
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18(4):600-14.
-
2008: Sirisabya N; Li Y; Jaishuen A; Zheng H G; Gershenson D M; Kavanagh J J
Tamoxifen is safe and effective in gynecological cancer patients with renal dysfunction.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18(4):648-51.
-
2008: Kavanagh J J; Sill M W; Ramirez P T; Warshal D; Pearl M L; Morgan M A
Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18(3):460-4.
-
2008: Jaishuen A; Berrios-Rivera J P; Sirisabya N; Zheng H G; Li Y; Kavanagh J J
Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18(2):379-83.
-
2008: Boruban M C; Jaishuen A; Sirisabya N; Li Y; Zheng H G; Deavers M T; Kavanagh J J
Ovarian endometriosis associated with carcinoma and sarcoma: case report.
European journal of gynaecological oncology 2008;29(4):393-6.
-
2008: Tangjitgamol Siriwan; Manusirivithaya Sumonmal; Hanprasertpong Jitti; Kavanagh John J
Hormone replacement therapy after treatment of endometrial cancer.
Gynecologic and obstetric investigation 2008;65(1):35-8.
-
2007: Kavanagh John J
Intraperitoneal chemotherapy in the treatment of ovarian cancer.
Journal of surgical oncology 2007;96(7):541-2.
-
2007: Li Yanfang; Finkel Kevin W; Hu Wei; Fu Siqing; Liu Jihong; Coleman Robert; Kavanagh John J
Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction.
Gynecologic oncology 2007;106(2):375-80.
-
2007: Li Y F; Fu S; Hu W; Liu J H; Finkel K W; Gershenson D M; Kavanagh J J
Systemic anticancer therapy in gynecological cancer patients with renal dysfunction.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2007;17(4):739-63.
-
2007: Zheng H; Kavanagh J J; Hu W; Liao Q; Fu S
Hormonal therapy in ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2007;17(2):325-38.
-
2006: Fu S; Kavanagh J J; Hu W; Bast R C
Clinical application of oxaliplatin in epithelial ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(5):1717-32.
-
2006: Wang X; Fu S; Freedman R S; Liu J; Kavanagh J J
Immunobiology of gestational trophoblastic diseases.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(4):1500-15.
-
2006: Chon Hye Sook; Hu Wei; Kavanagh John J
Targeted therapies in gynecologic cancers.
Current cancer drug targets 2006;6(4):333-63.
-
2006: Rosen Daniel G; Yang Gong; Deavers Michael T; Malpica Anais; Kavanagh John J; Mills Gordon B; Liu Jinsong
Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma.
Cancer 2006;106(9):1925-32.
-
2006: Coleman Robert L; Broaddus Russell R; Bodurka Diane C; Wolf Judith K; Burke Thomas W; Kavanagh John J; Levenback Charles F; Gershenson David M
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
Gynecologic oncology 2006;101(1):126-31.
-
2006: Fu Siqing; Hu Wei; Kavanagh John J; Bast Robert C
Targeting Aurora kinases in ovarian cancer.
Expert opinion on therapeutic targets 2006;10(1):77-85.
-
2006: Lee E-J; Deavers M T; Hughes J I; Lee J-H; Kavanagh J J
Metastasis to sigmoid colon mucosa and submucosa from serous borderline ovarian tumor: response to hormone therapy.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16 Suppl 1():295-9.
-
2005: Wang X; Tangjitgamol S; Liu J; Kavanagh J J
Response of recurrent uterine high-grade malignant mixed müllerian tumor to letrozole.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(6):1243-8.
-
2005: Tangjitgamol S; Erlichman J; Northrup H; Malpica A; Wang X; Lee E; Kavanagh J J
Benign multicystic peritoneal mesothelioma: cases reports in the family with diverticulosis and literature review.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(6):1101-7.
-
2005: Tangjitgamol S; Ramirez P T; Sun C C; See H T; Jhingran A; Kavanagh J J; Deavers M T
Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(4):646-56.
-
2005: Kavanagh J J; Gershenson D M; Choi H; Lewis L; Patel K; Brown G L; Garcia A; Spriggs D R
Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(4):593-600.
-
2005: Wang Xipeng; Wang Ena; Kavanagh John J; Freedman Ralph S
Ovarian cancer, the coagulation pathway, and inflammation.
Journal of translational medicine 2005;3():25.
-
2005: See H T; Freedman R S; Kudelka A P; Burke T W; Gershenson D M; Tangjitgamol S; Kavanagh J J
Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(2):209-16.
-
2005: Lee Eun-Ju; Mircean Cristian; Shmulevich Ilya; Wang Huamin; Liu Jinsong; Niemistö Antti; Kavanagh John J; Lee Je-Ho; Zhang Wei
Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion.
Molecular cancer 2005;4(1):7.
-
2005: Hu Wei; Kavanagh John J; Deaver Michael; Johnston Dennis A; Freedman Ralph S; Verschraegen Claire F; Sen Subrata
Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer.
Oncology research 2005;15(1):49-57.
-
2004: Hu Wei; Wu Weiguo; Kobayashi Ryuji; Kavanagh John J
Proteomics in cancer screening and management in gynecologic cancer.
Current oncology reports 2004;6(6):456-62.
-
2004: Tangjitgamol S; See H T; Manusirivithaya S; Levenback C F; Gershenson D M; Kavanagh J J
Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004;14(5):804-14.
-
2004: Tangjitgamol S; Levenback C F; Beller U; Kavanagh J J
Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature review.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004;14(3):399-422.
-
2004: Verschraegen Claire F; Kudelka Andrzej P; Hu Wei; Vincent Monique; Kavanagh John J; Loyer Evelyne; Bastien Luc; Duggal A; De Jager R
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
Cancer chemotherapy and pharmacology 2004;53(1):1-7.
-
2004: See Hui-Ti; Kavanagh John J
Novel agents in epithelial ovarian cancer.
Cancer investigation 2004;22 Suppl 2():29-44.
-
2003: Hu Wei; Kavanagh John J
Anticancer therapy targeting the apoptotic pathway.
The lancet oncology 2003;4(12):721-9.
-
2003: See H T; Kavanagh J J; Hu W; Bast R C
Targeted therapy for epithelial ovarian cancer: current status and future prospects.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13(6):701-34.
-
2003: Freedman Ralph S; Vadhan-Raj Saroj; Butts Cherie; Savary Cherylyn; Melichar Bohuslav; Verschraegen Claire; Kavanagh John J; Hicks Marshall E; Levy Lawrence B; Folloder Jody K; Garcia Michael E
Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(14):5228-37.
-
2003: Hu Wei; Wu WeiGuo; Verschraegen Claire F; Chen Ling; Mao Li; Yeung Sai-Ching Jim; Kudelka Andrzej P; Freedman Ralph S; Kavanagh John J
Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor.
Proteomics 2003;3(10):1904-11.
-
2003: Melichar Bohuslav; Lenzi Renato; Rosenblum Michael; Kudelka Andrzej P; Kavanagh John J; Melicharova Karolina; Templin Stacie; Garcia Michael E; Abbruzzese James L; Freedman Ralph S
Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-12.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(3):270-6.
-
2003: Montero A J; Díaz-Montero C M; Malpica A; Ramirez P T; Kavanagh J J
Langerhans cell histiocytosis of the female genital tract: a literature review.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13(3):381-8.
-
2003: Verschraegen Claire F; Hu Wei; Du Yu; Mendoza John; Early Janet; Deavers Michael; Freedman Ralph S; Bast Robert C; Kudelka Andrzej P; Kavanagh John J; Giovanella Beppino C
Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):845-52.
-
2003: Bodurka Diane C; Levenback Charles; Wolf Judith K; Gano Jacalyn; Wharton J Taylor; Kavanagh John J; Gershenson David M
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):291-7.
-
2002: Lenzi Renato; Rosenblum Michael; Verschraegen Claire; Kudelka Andrzej P; Kavanagh John J; Hicks Marshall E; Lang Eric A; Nash Michael A; Levy Lawrence B; Garcia Michael E; Platsoucas Chris D; Abbruzzese James L; Freedman Ralph S
Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(12):3686-95.
-
2002: Sun Charlotte C; Bodurka Diane C; Donato Michele L; Rubenstein Edward B; Borden Candice L; Basen-Engquist Karen; Munsell Mark F; Kavanagh John J; Gershenson David M
Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?
Gynecologic oncology 2002;87(1):118-28.
-
2002: Wu W; Hu W; Kavanagh J J
Proteomics in cancer research.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2002;12(5):409-23.
-
2002: Kavanagh John J
Docetaxel in the treatment of ovarian cancer.
Oncology (Williston Park, N.Y.) 2002;16(6 Suppl 6):73-81.
-
2002: Vadhan-Raj Saroj; Kavanagh John J; Freedman Ralph S; Folloder Jody; Currie Laura M; Bueso-Ramos Carlos; Verschraegen Claire F; Narvios Aida B; Connor Jerome; Hoots William K; Broemeling Lyle D; Lichtiger Benjamin
Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
Lancet 2002;359(9324):2145-52.
-
2002: Hu Wei; Wu Weiguo; Yeung Sai-Ching Jim; Freedman Ralph S; Kavanagh John J; Verschraegen Claire F
Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyl transferase inhibitor.
Anticancer research 2002;22(2A):665-72.
-
2002: Hu Wei; Verschraegen C F; Wu W G; Nash M; Freedman R S; Kudelka A; Kavanagh J J
Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2002;12(2):202-7.
-
2001: Verschraegen C F; Kavanagh J J; Loyer E; Bodurka-Bevers D; Kudelka A P; Hu W; Vincent M; Nelson T; Levenback C;
Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix.
Cancer 2001;92(9):2327-33.
-
2001: Verschraegen C F; Benjapibal M; Supakarapongkul W; Levy L B; Ross M; Atkinson E N; Bodurka-Bevers D; Kavanagh J J; Kudelka A P; Legha S S
Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2001;11(5):359-64.
-
2001: Azevedo P; Verschraegen C F; Kavanagh J J; Kudelka A P; Freedman R S; Lu K; Deavers M T
Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report.
European journal of gynaecological oncology 2001;22(5):319-21.
-
2000: Moon C; Verschraegen C F; Bevers M; Freedman R; Kudelka A P; Kavanagh J J
Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
Anti-cancer drugs 2000;11(7):565-8.
-
2000: Verschraegen C F; Sittisomwong T; Kudelka A P; Guedes E d; Steger M; Nelson-Taylor T; Vincent M; Rogers R; Atkinson E N; Kavanagh J J
Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(14):2733-9.
-
2000: Freedman R S; Kudelka A P; Kavanagh J J; Verschraegen C; Edwards C L; Nash M; Levy L; Atkinson E N; Zhang H Z; Melichar B; Patenia R; Templin S; Scott W; Platsoucas C D
Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(6):2268-78.
-
2000: Hu W; Wu W; Nash M A; Freedman R S; Kavanagh J J; Verschraegen C F
Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines.
Anticancer research 2000;20(2A):729-33.
-
2000: Vadhan-Raj S; Verschraegen C F; Bueso-Ramos C; Broxmeyer H E; Kudelkà A P; Freedman R S; Edwards C L; Gershenson D; Jones D; Ashby M; Kavanagh J J
Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.
Annals of internal medicine 2000;132(5):364-8.
-
2000: Hu W; McCrea P D; Deavers M; Kavanagh J J; Kudelka A P; Verschraegen C F
Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors.
Clinical & experimental metastasis 2000;18(1):83-8.
-
2000: Verschraegen C F; Levenback C; Vincent M; Wolf J; Bevers M; Loyer E; Kudelka A P; Kavanagh J J
Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan.
Annals of the New York Academy of Sciences 2000;922():349-51.
-
2000: Verschraegen C F; Vincent M; Abbruzzese J L; Siegler D; Kavanagh J J; Loyer E; Kudelka A P; Rubin E
Phase I study of 9-nitro-20(S)-camptothecin in combination with cisplatin for patients with advanced malignancies.
Annals of the New York Academy of Sciences 2000;922():345-8.
-
2000: Sittisomwong T; Suneja A; Kudelka A P; Verschraegen C F; Kavanagh J J
Estrogen replacement therapy and ovarian cancer.
European journal of gynaecological oncology 2000;21(4):348-54.
-
1999: Loercher A E; Nash M A; Kavanagh J J; Platsoucas C D; Freedman R S
Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(11):6251-60.
-
1999: Rosenblum M G; Verschraegen C F; Murray J L; Kudelka A P; Gano J; Cheung L; Kavanagh J J
Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(5):953-61.
-
1999: Verschraegen C F; Gupta E; Loyer E; Kavanagh J J; Kudelka A P; Freedman R S; Edwards C L; Harris N; Steger M; Steltz V; Giovanella B C; Stehlin J S
A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer.
Anti-cancer drugs 1999;10(4):375-83.
-
1998: Kudelka A P; Vasuratna A; Edwards C L; Augustine K; Benjapibal M; Verschraegen C F; Kavanagh J J
Gemcitabine after bone marrow transplantation for refractory juvenile granulosa cell tumor.
Anti-cancer drugs 1998;9(7):621-3.
-
1998: Kavanagh J J; Verschraegen C F; Kudelka A P
Irinotecan in cervical cancer.
Oncology (Williston Park, N.Y.) 1998;12(8 Suppl 6):94-8.
-
1998: Benjapibal M; Kudelka A P; Vasuratna A; Edwards C L; Verschraegen C F; Valero V; Vadhan-Raj S; Kavanagh J J
Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer.
Anti-cancer drugs 1998;9(6):577-9.
-
1998: Verschraegen C F; Vasuratna A; Edwards C; Freedman R; Kudelka A P; Tornos C; Kavanagh J J
Clinicopathologic analysis of mullerian adenosarcoma: the M.D. Anderson Cancer Center experience.
Oncology reports 1998;5(4):939-44.
-
1998: Kudelka A P; Hasenburg A; Verschraegen C F; Edwards C L; Meyers C A; Varma D; Freedman R S; Forman A; Conrad C A; Grove W; Grothey A; Kavanagh J J
Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma.
Anti-cancer drugs 1998;9(5):405-9.
-
1998: Nash M A; Lenzi R; Edwards C L; Kavanagh J J; Kudelka A P; Verschraegen C F; Platsoucas C D; Freedman R S
Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines.
Clinical and experimental immunology 1998;112(2):172-80.
-
1998: Vasuratna A; Kudelka A P; Edwards C L; Wootipoom V; Verschraegen C F; Charnsangavej C; Kavanagh J J
Prolonged remission of endometrial cancer with paclitaxel and carboplatin.
Anti-cancer drugs 1998;9(3):283-5.
-
1998: Melichar B; Savary C; Kudelka A P; Verschraegen C; Kavanagh J J; Edwards C L; Platsoucas C D; Freedman R S
Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):799-809.
-
1998: Verschraegen C F; Natelson E A; Giovanella B C; Kavanagh J J; Kudelka A P; Freedman R S; Edwards C L; Ende K; Stehlin J S
A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor.
Anti-cancer drugs 1998;9(1):36-44.
-
1997: Ferrandina G; Melichar B; Loercher A; Verschraegen C F; Kudelka A P; Edwards C L; Scambia G; Kavanagh J J; Abbruzzese J L; Freedman R S
Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro.
Cancer research 1997;57(19):4309-15.
-
1997: Kudelka A P; Levy T; Verschraegen C F; Edwards C L; Piamsomboon S; Termrungruanglert W; Freedman R S; Kaplan A L; Kieback D G; Meyers C A; Jaeckle K A; Loyer E; Steger M; Mante R; Mavligit G; Killian A; Tang R A; Gutterman J U; Kavanagh J J
A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(9):1501-5.
-
1997: Kudelka A P; Winn R; Edwards C L; Downey G; Greenberg H; Dakhil S R; Freedman R S; LoCoco S; Umbreit J; Delmore J E; Arbuck S; Loyer E; Gacrama P; Fueger R; Kavanagh J J
An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix.
Anti-cancer drugs 1997;8(7):657-61.
-
1997: Kudelka A P; Siddik Z H; Tresukosol D; Edwards C L; Freedman R S; Madden T L; Rastogi R; Hord M; Kim E E; Tornos C; Mante R; Kavanagh J J
A phase II and pharmacokinetic study of enloplatin in patients with platinum refractory advanced ovarian carcinoma.
Anti-cancer drugs 1997;8(7):649-56.
-
1997: van Besien K; Verschraegen C; Mehra R; Giralt S; Kudelka A P; Edwards C L; Piamsonboom S; Termrungruanglert W; Champlin R; Kavanagh J J
Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue.
Gynecologic oncology 1997;65(2):366-9.
-
1997: Termrungruanglert W; Kudelka A P; Edwards C L; Delclos L; Verschraegen C F; Kavanagh J J
Gynecologic cancer in the elderly.
Clinics in geriatric medicine 1997;13(2):363-79.
-
1997: Ashour A A; Verschraegen C F; Kudelka A P; Kavanagh J J
Paraneoplastic syndromes of gynecologic neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1272-82.
-
1997: Verschraegen C F; Levy T; Kudelka A P; Llerena E; Ende K; Freedman R S; Edwards C L; Hord M; Steger M; Kaplan A L; Kieback D; Fishman A; Kavanagh J J
Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):625-31.
-
1997: Piamsomboon S; Kudelka A P; Termrungruanglert W; Van Besien K; Edwards C L; Lifshitz S; Schomer D F; Champlin R; Mante R P; Kavanagh J J; Verschraegen C F
Remission of refractory gestational trophoblastic disease in the brain with ifosfamide, carboplatin, and etoposide (ICE): first report and review of literature.
European journal of gynaecological oncology 1997;18(6):453-6.
-
1997: Balat O; Kudelka A P; Edwards C L; Verschraegen C F; Kavanagh J J
Prolonged remission of platinum-refractory ovarian cancer with docetaxel: brief report and review of literature.
European journal of gynaecological oncology 1997;18(5):341-2.
-
1997: Termrungruanglert W; Kudelka A P; Piamsomboon S; Edwards C L; Tornos C; Kavanagh J J
Prolonged oral etoposide for advanced uterine leiomyosarcoma with pulmonary metastases: case report.
European journal of gynaecological oncology 1997;18(2):97-100.
-
1997: Llerena E; Kudelka A P; Tornos C; Cedillo G F; Lopez A; Edwards C L; Litam J P; Kavanagh J J
Remission of a chemotherapy resistant tumor of low malignant potential with tamoxifen.
European journal of gynaecological oncology 1997;18(1):23-5.
-
1996: Freedman R S; Gibbons J A; Giedlin M; Kudelka A P; Kavanagh J J; Edwards C L; Carrasco C H; Nash M A; Platsoucas C D
Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(6):443-51.
-
1996: Kudelka A P; Termrungruanglert W; Vadhan-Raj S; Edwards C L; Varma D G; Tornos C; Verschraegen C F; Kavanagh J J
Remission of advanced uterine leiomyosarcoma with pulmonary metastases with carboplatin and paclitaxel.
Anti-cancer drugs 1996;7(8):885-9.
-
1996: Wright-Browne V; Kudelka A P; Malpica A; Edwards C L; Varma D G; Kavanagh J J
Persistent partial molar pregnancy. A report of uterus-preserving treatment and follow-up with magnetic resonance imaging.
American journal of clinical oncology 1996;19(5):534-9.
-
1996: Piamsomboon S; Termrungruanglert W; Kudelka A P; Edwards C L; Freedman R S; Mountain C F; Delclos L; Aapro M S; DeCaro L; Bianca J; Verschraegen C F; Kavanagh J J
Prolonged stabilization of progressive squamous cell cancer of the cervix with interferon-alpha and 13-cis-retinoic acid: report of two cases and review of the literature.
Anti-cancer drugs 1996;7(7):800-4.
-
1996: Kudelka A P; Winn R; Edwards C L; Downey G; Greenberg H; Dakhil S R; Freedman R S; Loyer E; Rusinkiewicz J; Gacrama P; Fueger R; Kavanagh J J
Activity of paclitaxel in advanced or recurrent squamous cell cancer of the cervix.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(8):1285-8.
-
1996: Verschraegen C F; Kudelka A P; Termrungruanglert W; de Leon C G; Edwards C L; Freedman R S; Kavanagh J J; Vadhan-Raj S
Effects of interleukin-1 alpha on ovarian carcinoma in patients with recurrent disease.
European journal of cancer (Oxford, England : 1990) 1996;32A(9):1609-11.
-
1996: Termrungruanglert W; Kudelka A P; Piamsomboon S; Verschraegen C F; Edwards C L; Lifshitz S; Mante R P; Kavanagh J J
Remission of refractory gestational trophoblastic disease with high-dose paclitaxel.
Anti-cancer drugs 1996;7(5):503-6.
-
1996: Kudelka A P; Verschraegen C F; Levy T; Edwards C L; Fishman A; Freedman R S; Kaplan A; Kieback D G; Mante R; Ende K; Steger M; Kavanagh J J
Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix.
Anti-cancer drugs 1996;7(4):398-401.
-
1996: Fishman A; Kudelka A P; Tresukosol D; Edwards C L; Freedman R S; Kaplan A L; Girtanner R E; Kavanagh J J
Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor.
The Journal of reproductive medicine 1996;41(6):393-6.
-
1996: Kavanagh J J; Kudelka A P; de Leon C G; Tresukosol D; Hord M; Finnegan M B; Kim E E; Varma D; Forman A; Cohen P; Edwards C L; Freedman R S; Verschraegen C F
Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(5):837-42.
-
1996: Tresukosol D; Kudelka A P; Edwards C L; Silva E G; Kanojia M; Kavanagh J J
Leuprolide acetate in advanced ovarian serous tumor of low malignant potential. A case report.
The Journal of reproductive medicine 1996;41(5):363-6.
-
1996: Kudelka A P; Tresukosol D; Edwards C L; Freedman R S; Levenback C; Chantarawiroj P; Gonzalez de Leon C; Kim E E; Madden T; Wallin B; Hord M; Verschraegen C; Raber M; Kavanagh J J
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(5):1552-7.
-
1996: Kudelka A P; Tresukosol D; Gonzalez de Leon C; Termrungruanglert W; Edwards C L; Freedman R S; Tornos C; Kavanagh J J
Paclitaxel in patients with platinum-resistant ovarian cancer: a selected review of literature and clinical experience.
Journal of the Medical Association of Thailand = Chotmaihet thangphaet 1996;79(4):240-5.
-
1996: Termrungruanglert W; Kudelka A P; Piamsomboon S; Edwards C L; Verschraegen C F; Loyer E; Kavanagh J J
Remission of recurrent cervical cancer with paclitaxel and carboplatin: a case report and review of literature.
European journal of gynaecological oncology 1996;17(6):493-6.
-
1996: Lin Y C; Kudelka A P; Lawrence D; Verschraegen C F; Kavanagh J J; Edwards C L; Mante R; Freedman R S
Transcatheter arterial embolization for the control of life-threatening pelvic hemorrhage in a patient with locally advanced cervix carcinoma.
European journal of gynaecological oncology 1996;17(6):480-3.
-
1996: Balat O; Kudelka A P; Edwards C L; Verschraegen C; Kavanagh J J
Remission of recurrent mixed germ cell tumor of the ovary after treatment with vincristine, carboplatin, fluorouracil, and ifosfamide: a case report and review of the literature.
European journal of gynaecological oncology 1996;17(5):342-4.
-
1996: Balat O; Verschraegen C F; Edwards C L; Silva E; Kudelka A P; Kavanagh J J
Unusual presentation of a metastatic choriocarcinoma following a full term pregnancy: a case report.
European journal of gynaecological oncology 1996;17(4):271-3.
-
1996: Balat O; Kudelka A P; Tunca J C; Edwards C L; Verschraegen C; Kavanagh J J
Prolonged stabilization of progressive platinum-refractory ovarian cancer with paclitaxel: brief report.
European journal of gynaecological oncology 1996;17(4):264-6.
-
1996: Balat O; Kudelka A P; Ro J Y; Edwards C L; Balbay D; Dinney C; Kavanagh J J
Two synchronous primary tumors of the ovary and kidney: a case report.
European journal of gynaecological oncology 1996;17(4):257-9.
-
1996: Balat O; Kudelka A P; Edwards C L; Verschraegen C; Mante R; Kavanagh J J
A case report of paclitaxel administered to a patient with platinum-refractory ovarian cancer on long-term hemodialysis.
European journal of gynaecological oncology 1996;17(3):232-3.
-
1996: Tresukosol D; Kudelka A P; Gonzales de Leon C; Edwards C L; Freedman R S; Mante R; Hord M; Kavanagh J J
Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer.
European journal of gynaecological oncology 1996;17(3):188-91.
-
1996: Balat O; Kudelka A P; Edwards C L; Silva E; Kavanagh J J
Malignant transformation in endometriosis of the urinary bladder: case report of clear cell adenocarcinoma.
European journal of gynaecological oncology 1996;17(1):13-6.
-
1995: Romero J A; Kim E E; Tresukosol D; Kudelka A P; Edwards C L; Kavanagh J J
Recurrent ovarian endodermal sinus tumor: demonstration by computed tomography, magnetic resonance imaging, and positron emission tomography.
European journal of nuclear medicine 1995;22(10):1214-7.
-
1995: Tresukosol D; Kudelka A P; Malpica A; Varma D G; Edwards C L; Kavanagh J J
Leuprolide acetate and intravascular leiomyomatosis.
Obstetrics and gynecology 1995;86(4 Pt 2):688-92.
-
1995: Gershenson D M; Morris M; Burke T W; Levenback C; Kavanagh J J; Fromm G L; Silva E G; Warner D; Wharton J T
Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer.
Gynecologic oncology 1995;58(3):349-55.
-
1995: Kudelka A P; Siddik Z M; Balat O; Kavanagh J J
Carboplatin dosimetry in renal failure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(8):2147-8.
-
1995: Lin Y C; Kudelka A P; Tresukosol D; Malpica A; Carrasco C H; Lawrence D D; Collier R E; Munoz A; Delclos L; Kavanagh J J
Prolonged stabilization of progressive endometrial stromal sarcoma with prolonged oral etoposide therapy.
Gynecologic oncology 1995;58(2):262-5.
-
1995: Tresukosol D; Kudelka A P; Edwards C L; Fromm G L; Mante R; Kavanagh J J
Primary fallopian tube adenocarcinoma: clinical complete response after salvage treatment with high-dose paclitaxel.
Gynecologic oncology 1995;58(2):258-61.
-
1995: Chantarawiroj P; Tresukosol D; Kudelka A P; Edwards C L; Silva E G; Wharton J T; Kavanagh J J
Prolonged oral etoposide for refractory advanced uterine leiomyosarcoma.
Gynecologic oncology 1995;58(2):248-50.
-
1995: Kavanagh J J; Edwards C L; Freedman R S; Finnegan M B; Balat O; Tresukosol D; Burk K; Loechner S; Hord M; Franklin J L
A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer.
Gynecologic oncology 1995;58(1):106-9.
-
1995: Morris M; Eifel P J; Burke T W; McNamara M M; Levenback C; Kavanagh J J; Gershenson D M
Treatment of locally advanced cervical cancer with concurrent radiation and intra-arterial chemotherapy.
Gynecologic oncology 1995;57(1):72-8.
-
1995: Vassilopoulou-Sellin R; Kudelka A P; Kavanagh J J; Edwards C L; Vadhan-Raj S
Effects of interleukin-1 alpha administration on pituitary-adrenal and pituitary-thyroid axes function of patients with ovarian cancer.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;17(2):109-13.
-
1995: Wilailak S; Kudelka A P; Donner L R; Silva E; Mante R; Kavanagh J J
Peritoneal papillary serous carcinoma: response to Taxol in platinum resistant disease.
European journal of gynaecological oncology 1995;16(3):187-9.
-
1994: Eisenhauer E A; Lippman S M; Kavanagh J J; Parades-Espinoza M; Arnold A; Hong W K; Massimini G; Schleuniger U; Bollag W; Holdener E E
Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(10):1622-5.
-
1994: Freedman R S; Edwards C L; Kavanagh J J; Kudelka A P; Katz R L; Carrasco C H; Atkinson E N; Scott W; Tomasovic B; Templin S
Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(3):198-210.
-
1994: Moore D M; Kalvakolanu D V; Lippman S M; Kavanagh J J; Hong W K; Borden E C; Paredes-Espinoza M; Krakoff I H
Retinoic acid and interferon in human cancer: mechanistic and clinical studies.
Seminars in hematology 1994;31(4 Suppl 5):31-7.
-
1994: Romero J A; Kim E E; Kudelka A P; Edwards C L; Kavanagh J J
MRI of recurrent cystic mesothelioma: differential diagnosis of cystic pelvic masses.
Gynecologic oncology 1994;54(3):377-80.
-
1994: Vadhan-Raj S; Kudelka A P; Garrison L; Gano J; Edwards C L; Freedman R S; Kavanagh J J
Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(4):707-14.
-
1994: Paredes Espinoza M; Lippman S M; Kavanagh J J; Delgadillo Madrueño F; Paredes Casillas P; Bañuelos Acosta O; Alvarez Márquez V; Buenrostro Ahued M A; de Alba Ayala I; Arias Castro G
[Treatment of 32 cervico-uterine cancer patients with 13-cis-retinoic acid and interferon alpha]
Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición 1994;46(2):105-11.
-
1994: Eisenhauer E A; Lippman S M; Kavanagh J J; Parades-Espinoza M; Arnold A; Hong W K; Massimini G; Schleuniger U; Bollag W; Holdener E E
Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8 Suppl 3():S38-41.
-
1993: Burke T W; Munkarah A; Kavanagh J J; Morris M; Levenback C; Tornos C; Gershenson D M
Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin.
Gynecologic oncology 1993;51(3):397-400.
-
1993: Kavanagh J J; Kudelka A P
Systemic therapy for gynecologic cancer.
Current opinion in oncology 1993;5(5):891-9.
-
1993: Roman L D; Mitchell M F; Tornos C; Glover A; Kavanagh J J
Dedifferentiated extrauterine adenosarcoma responsive to chemotherapy.
Gynecologic oncology 1993;49(3):389-94.
-
1993: Kirk I R; Carrasco C H; Lawrence D D; Chuang V P; Richli W R; Charnsangavej C; Kavanagh J J; Kudelka A P; Freedman R S; Markowitz A B
Intraperitoneal catheters: percutaneous placement with fluoroscopic guidance.
Journal of vascular and interventional radiology : JVIR 1993;4(2):299-304.
-
1993: Lippman S M; Kavanagh J J; Paredes-Espinoza M; Delgadillo-Madrueño F; Paredes-Casillas P; Hong W K; Massimini G; Holdener E E; Krakoff I H
13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix.
Journal of the National Cancer Institute 1993;85(6):499-500.
-
1993: Gershenson D M; Mitchell M F; Atkinson N; Silva E G; Burke T W; Morris M; Kavanagh J J; Warner D; Wharton J T
Age contrasts in patients with advanced epithelial ovarian cancer. The M.D. Anderson Cancer Center experience.
Cancer 1993;71(2 Suppl):638-43.
-
1993: Smith H O; Stringer C A; Kavanagh J J; Gershenson D M; Edwards C L; Wharton J T
Treatment of advanced or recurrent squamous cell carcinoma of the uterine cervix with mitomycin-C, bleomycin, and cisplatin chemotherapy.
Gynecologic oncology 1993;48(1):11-5.
-
1993: Lippman S M; Glisson B S; Kavanagh J J; Lotan R; Hong W K; Paredes-Espinoza M; Hittelman W N; Holdener E E; Krakoff I H
Retinoic acid and interferon combination studies in human cancer.
European journal of cancer (Oxford, England : 1990) 1993;29A Suppl 5():S9-13.
-
1992: Gershenson D M; Mitchell M F; Atkinson N; Silva E G; Kavanagh J J; Morris M; Burke T W; Warner D; Wharton J T
The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: "maintenance" therapy reconsidered.
Gynecologic oncology 1992;47(1):7-13.
-
1992: Levenback C; Burke T W; Silva E; Morris M; Gershenson D M; Kavanagh J J; Wharton J T
Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC).
Gynecologic oncology 1992;46(3):317-21.
-
1992: Lippman S M; Kavanagh J J; Paredes-Espinoza M; Delgadillo-Madrueño F; Paredes-Casillas P; Hong W K; Holdener E; Krakoff I H
13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix.
Journal of the National Cancer Institute 1992;84(4):241-5.
-
1991: Rosenblum M G; Kavanagh J J; Burke T W; Wharton J T; Cunningham J E; Shanken L J; Silva E G; Thompson L; Cheung L; Lamki L
Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administration.
Journal of the National Cancer Institute 1991;83(22):1629-36.
-
1991: Patton T J; Kavanagh J J; Delclos L; Wallace S; Haynie T P; Gershenson D M; Wharton J T; Bass S
Five-year survival in patients given intra-arterial chemotherapy prior to radiotherapy for advanced squamous carcinoma of the cervix and vagina.
Gynecologic oncology 1991;42(1):54-9.
-
1991: Burke T W; Stringer C A; Morris M; Freedman R S; Gershenson D M; Kavanagh J J; Edwards C L
Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide.
Gynecologic oncology 1991;40(3):264-7.
-
1991: Baiocchi G; Kavanagh J J; Talpaz M; Wharton J T; Gutterman J U; Kurzrock R
Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies.
Cancer 1991;67(4):990-6.
-
1990: Morris M; Gershenson D M; Burke T W; Kavanagh J J; Silva E G; Wharton J T
Treatment of fallopian tube carcinoma with cisplatin, doxorubicin, and cyclophosphamide.
Obstetrics and gynecology 1990;76(6):1020-4.
-
1990: Lee J H; Kavanagh J J; Wildrick D M; Wharton J T; Blick M
Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas.
Cancer research 1990;50(9):2724-8.
-
1990: Gershenson D M; Morris M; Cangir A; Kavanagh J J; Stringer C A; Edwards C L; Silva E G; Wharton J T
Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(4):715-20.
-
1989: Gershenson D M; Kavanagh J J; Copeland L J; Stringer C A; Morris M; Wharton J T
Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy.
Obstetrics and gynecology 1989;73(5 Pt 1):798-802.
-
1989: Kavanagh J J; Nicaise C
Carboplatin in refractory epithelial ovarian cancer.
Seminars in oncology 1989;16(2 Suppl 5):45-8.
-
1989: Gershenson D M; Wharton J T; Copeland L J; Stringer C A; Edwards C L; Kavanagh J J; Freedman R S
Treatment of advanced epithelial ovarian cancer with cisplatin and cyclophosphamide.
Gynecologic oncology 1989;32(3):336-41.
-
1989: Lee J H; Kavanagh J J; Wharton J T; Wildrick D M; Blick M
Allele loss at the c-Ha-ras1 locus in human ovarian cancer.
Cancer research 1989;49(5):1220-2.
-
1989: Kavanagh J J; Roberts W; Townsend P; Hewitt S
Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(1):115-8.
-
1987: Gershenson D M; Copeland L J; Kavanagh J J; Stringer C A; Saul P B; Wharton J T
Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide.
Obstetrics and gynecology 1987;70(5):765-9.
-
1987: Kavanagh J J; Saul P B; Wharton J T; Rutledge F N
A trial of continuous-infusion vinblastine in refractory endometrial adenocarcinoma.
Gynecologic oncology 1987;26(2):236-9.
-
1986: Gordon A N; Kavanagh J J; Gershenson D M; Saul P B; Copeland L J; Stringer C A
Cisplatin, vinblastine, and bleomycin combination therapy in resistant gestational trophoblastic disease.
Cancer 1986;58(7):1407-10.
-
1986: Gershenson D M; Kavanagh J J; Copeland L J; Del Junco G; Cangir A; Saul P B; Stringer C A; Edwards C L; Wharton J T
Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vinblastine, bleomycin, and cisplatin.
Cancer 1986;57(9):1731-7.
-
1985: Gershenson D M; Copeland L J; Kavanagh J J; Cangir A; Del Junco G; Saul P B; Stringer C A; Freedman R S; Edwards C L; Wharton J T
Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vincristine, dactinomycin, and cyclophosphamide.
Cancer 1985;56(12):2756-61.
-
1985: Copeland L J; Sneige N; Stringer C A; Gershenson D M; Saul P B; Kavanagh J J
Alveolar rhabdomyosarcoma of the female genitalia.
Cancer 1985;56(4):849-55.
-
1985: Kavanagh J J; Copeland L J; Gershenson D M; Saul P B; Wharton J T; Rutledge F N
Continuous-infusion vinblastine in refractory carcinoma of the cervix: a phase II trial.
Gynecologic oncology 1985;21(2):211-4.
-
1985: Copeland L J; Sneige N; Ordonez N G; Hancock K C; Gershenson D M; Saul P B; Kavanagh J J
Endodermal sinus tumor of the vagina and cervix.
Cancer 1985;55(11):2558-65.
-
1985: Gordon A N; Gershenson D M; Copeland L J; Saul P B; Kavanagh J J; Edwards C L
High-risk metastatic gestational trophoblastic disease.
Obstetrics and gynecology 1985;65(4):550-6.
Sign-in to see more
